This study evaluates the prophylactic effect of exogenous L-CARNOSINE in Oxaliplatin induced peripheral neuropathy, Thus half of the patients will receive L-CARNOSINE with Oxaliplatin and the other half will not receive L-CARNOSINE with their chemotherapy (oxaliplatin),And then neuropathy together with some oxidative stress markers will be assessed at the end of treatment duration (three months) .
Full Title of Study: “The Potential Prophylactic Effect of Exogenous Antioxidant ”L-CARNOSINE” on Oxaliplatin-induced Peripheral Neuropathy in Cancer Patients”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: None (Open Label)
- Study Primary Completion Date: November 2016
Oxaliplatin causes peripheral neuropathy , L-CARNOSINE is supposed to prevent this side effect possibly by reducing oxidative stress and enhancing the growth of nerves.This study is intended to clarify the effect and mechanism of action of L-CARNOSINE in preventing Oxaliplatin induced peripheral neuropathy in cancer patients.
Blood samples will be collected from the patients before starting the chemotherapy and at the end of treatment duration (3 months) and then oxidative stress markers will be measured in these samples
- Drug: L-CARNOSINE
- L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
Arms, Groups and Cohorts
- Experimental: Treatment group
- this arm will receive L-CARNOSINE PO (each patient will receive 1 tablet daily and each tablet contains 500 mg thus a total of 500 mg per day) together with their chemotherapy wich is oxaliplatin.
- No Intervention: Control group
- This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.
Clinical Trial Outcome Measures
- Assessment of peripheral neuropathy using neuropathy grading score “CTCAE”, version 4.0) also oxidative stress markers will be measured by ELISA kits.
- Time Frame: Three months
- The following markers will be measured by ELISA kits : Nrf2 induced oxidative stress pathways (GSH) NF-KB anti-inflammatory pathway (TNF- alpha) pro-apoptic signals (caspase 3)
- Assessment of tumor markers (CA,CEA) in blood.
- Time Frame: Three months
- Tumor Markers (CA,CEA) will be assessed at the end of treatment duration to make sure that L-CARNOSINE didn’t interfere with the patients’ response to chemotherapy.
Participating in This Clinical Trial
Patients are eligible to be enrolled in this study, if they meet the following criteria
1. Elderly males and females with age (˃18 and ˂60).
2. Cancer patients treated with oxaliplatin for the first time (dose 85- 135mg/m2) administered every two to three weeks for 3 months.
Excluded from this study are the patients with the following Criteria:
- Suffering from diabetes mellitus.
- Suffering from peripheral neuropathy as a result of any other disease or drug.
- Suffering from severe renal impairment (CrCl ˂ 30 ml/min).
- Suffering from epilepsy.
- Taking vitamin B.
- Who previously took Oxaliplatin or any other chemotherapeutic agent that causes peripheral neuropathy.
- Taking antidepressants or MAOI's.
- Taking NSAIDs, paracetamol, opiates or any other analgesics or pain killers.
- Pregnant or lactating patients.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Cairo University
- Misr International University
- Provider of Information About this Clinical Study
- Principal Investigator: Rana Magdy, Teaching assistant – Misr International University
- Overall Official(s)
- Samira Saleh, Professor, Study Director, Cairo University
- Hanan elabhar, Professor, Study Chair, Cairo University
- Mona Schaalan, assoc. prof., Study Chair, Misr International University
- Amr Shafik, Assoc. Prof, Study Chair, Ain Shams University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.